Global Patent Index - EP 0981337 A4

EP 0981337 A4 20030312 - ENHANCED ANTI-ANGIOGENIC ACTIVITY OF PERMANENTLY CHARGED DERIVATIVES OF STEROID HORMONES

Title (en)

ENHANCED ANTI-ANGIOGENIC ACTIVITY OF PERMANENTLY CHARGED DERIVATIVES OF STEROID HORMONES

Title (de)

ERHOEHTE ANTI-ANGIOGENE AKTIVITAET VON PERMANENT GELADENEN STEROIDHORMONDERIVATEN

Title (fr)

ACTIVITE ANTI-ANGIOGENIQUE AMELIOREE DES DERIVES CONSTAMMENT CHARGES D'HORMONES STEROIDIENNES

Publication

EP 0981337 A4 20030312 (EN)

Application

EP 98903921 A 19980204

Priority

  • IL 12018497 A 19970209
  • US 9802176 W 19980204
  • US 83307497 A 19970402

Abstract (en)

[origin: WO9834583A2] The present invention discloses the use of permanently charged steroid agonists or antagonists as potent anti-angiogenic compositions comprising as an active ingredient a compound of general formulae (I, II or III), wherein DRUG is any steroid agonist or antagonist, a mixed agonist-antagonist, or a partial agonist and the substituents are as defined in the specification.

IPC 1-7

A61K 31/40; A61P 5/32; A61P 7/00; A61P 15/00; A61P 19/02; A61P 27/02; A61P 29/00; A61P 35/04; A61P 17/06

IPC 8 full level

A61P 5/32 (2006.01); A61K 31/14 (2006.01); A61P 9/00 (2006.01); A61P 15/08 (2006.01); A61P 17/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 27/02 (2006.01)

CPC (source: EP)

A61K 31/14 (2013.01); A61P 5/32 (2017.12); A61P 7/00 (2017.12); A61P 9/00 (2017.12); A61P 15/00 (2017.12); A61P 15/08 (2017.12); A61P 17/00 (2017.12); A61P 17/06 (2017.12); A61P 19/02 (2017.12); A61P 27/02 (2017.12); A61P 29/00 (2017.12); A61P 35/04 (2017.12); A61P 43/00 (2017.12)

Citation (search report)

  • [YD] US 4536516 A 19850820 - HARPER MICHAEL J K [FR], et al
  • [Y] WO 9409764 A1 19940511 - NIPPON KAYAKU KK [JP], et al
  • [Y] US 2914561 A 19591124 - ALLEN ROBERT E, et al
  • [Y] US 2971001 A 19610207 - PATRICK PALOPOLI FRANK, et al
  • [XD] BIEGON ANAT ET AL: "A permanently charges tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents.", CANCER RESEARCH, vol. 56, no. 19, 1996, pages 4328 - 4331, XP001121764, ISSN: 0008-5472
  • [X] BREWSTER M E ET AL: "Tamoxifen methiodide-induced necrosis and fibrosis in implanted human breast tumors, an MRI study.", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 13, no. 9 SUPPL., 1996, Annual Meeting of the American Association of Pharmaceutical Scientists;Seattle, Washington, USA; October 27-31, 1996, pages S492, XP009003325, ISSN: 0724-8741
  • [X] BREWSTER M E ET AL: "Mechanisms of action of quaternary derivatives of tamoxifen.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 212, no. 1-2, 1996, 212th American Chemical Society National Meeting;Orlando, Florida, USA; August 25-29, 1996, pages MEDI 43, XP009003601, ISSN: 0065-7727
  • [YD] GAGLIARDI A ET AL: "INHIBITION OF ANGIOGENESIS BY ANTIESTROGENS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, 1 February 1993 (1993-02-01), pages 533 - 535, XP001121715, ISSN: 0008-5472
  • [Y] FOLKMAN J: "WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT?", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 82, 3 January 1990 (1990-01-03), pages 4 - 6, XP000943514, ISSN: 0027-8874
  • [Y] WEIDNER N ET AL: "TUMOR ANGIOGENESIS AND METASTASIS CORRELATION IN INVASIVE BREAST CARCINOMA", NEW ENGLAND JOURNAL OF MEDICINE, vol. 324, no. 1, 1991, pages 1 - 8, XP009003719, ISSN: 0028-4793
  • See references of WO 9834583A2

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9834583 A2 19980813; WO 9834583 A3 19981105; AU 6056298 A 19980826; AU 746007 B2 20020411; CA 2280181 A1 19980813; EP 0981337 A2 20000301; EP 0981337 A4 20030312; JP 2001511182 A 20010807

DOCDB simple family (application)

US 9802176 W 19980204; AU 6056298 A 19980204; CA 2280181 A 19980204; EP 98903921 A 19980204; JP 53487698 A 19980204